Scarica l'app Stockscreener
1.32
2.33%
0.03
Dopo l'orario di chiusura:
1.30
-0.02
-1.52%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché PHIO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.29
Aprire:
$1.27
Volume 24 ore:
134.87K
Relative Volume:
0.04
Capitalizzazione di mercato:
$15.33M
Reddito:
-
Utile/perdita netta:
$-8.70M
Rapporto P/E:
-0.8777
EPS:
-1.5039
Flusso di cassa netto:
$-7.99M
1 W Prestazione:
+1.54%
1M Prestazione:
+12.82%
6M Prestazione:
-41.07%
1 anno Prestazione:
-45.68%
Intervallo 1D:
$1.25
$1.34
Intervallo di 1 settimana:
$1.20
$1.34
Portata 52W:
$0.8127
$4.1899
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Nome
Phio Pharmaceuticals Corp
Settore
Industria
Telefono
(508) 767-3861
Indirizzo
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.32 | 14.99M | 0 | -8.70M | -7.99M | -1.5039 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-05 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-05 | Iniziato | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Borsa (PHIO) Ultime notizie
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026 - TMX Newsfile
PHIO: RNA immunotherapy shows strong tumor clearance and safety, advancing to next clinical phase - TradingView — Track All Markets
Phio Pharmaceuticals to Discuss 'Nobel Prize Winning Science' for Skin Cancer Treatment - National Today
EPS Watch: Is Phio Pharmaceuticals Corp a stock for growth or value investors2026 Trade Ideas & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026 - TMX Newsfile
Phio spotlights skin cancer candidate after 65% response rate - Stock Titan
Phio CEO heads to Nasdaq Marketsite for April 14 investor presentation - Stock Titan
Ideas Watch: Does Phio Pharmaceuticals Corp have declining or rising EPSNew Guidance & Risk Controlled Swing Alerts - baoquankhu1.vn
Phio Pharmaceuticals Corp. Enters Material Definitive Agreement – SEC 8-K Filing Details April 8, 2026 - Minichart
Phio Pharmaceuticals Establishes New At-the-Market Equity Program - TipRanks
Phio Pharmaceuticals CorpEnters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026 - TradingView — Track All Markets
Phio Pharmaceuticals (NASDAQ: PHIO) launches $6.36M at-the-market stock plan - Stock Titan
Phio Pharmaceuticals (PHIO) files $6.36M ATM with H.C. Wainwright - Stock Titan
Pyramid Pharma Services Announces Drug Product Manufacturing Agreement for Phio Pharmaceuticals’ Lead Oncology - EIN News
What dividend growth rate does Phio Pharmaceuticals Corp offer2026 Chart Watch & Real-Time Stock Entry Alerts - baoquankhu1.vn
Profit Review: Is Phio Pharmaceuticals Corp on track to beat earningsSwing Trade & Detailed Earnings Play Alerts - baoquankhu1.vn
VIX Spike: Is Phio Pharmaceuticals Corp being accumulated by smart moneyQuarterly Risk Review & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
PHIO Stock Price, Quote & Chart | PHIO PHARMACEUTICALS CORP (NASDAQ:PHIO) - ChartMill
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762 - The National Law Review
Phio Pharmaceuticals Secures cGMP Manufacturing for Clinical Supply - The Globe and Mail
Phio Pharmaceuticals Signs U.S. cGMP Manufacturing Agreement for PH-762 Drug Product Clinical Supply - Minichart
Phio Pharmaceuticals secures U.S. cGMP manufacturer for PH-762 clinical and commercial supply - TradingView — Track All Markets
Phio (NASDAQ: PHIO) inks PH-762 manufacturing deal after strong 65% response - Stock Titan
Phio lines up U.S. supply for skin cancer drug as PH-762 trials advance - Stock Titan
Dow Update: Can Phio Pharmaceuticals Corp lead its sector in growth - baoquankhu1.vn
Phio Pharmaceuticals Corp (44R1.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Phio Pharmaceuticals Corp (44R1.MU) stock price, news, quote and history - Yahoo Finance UK
Financial Analysis: Galectin Therapeutics (NASDAQ:GALT) & Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Phio Pharmaceuticals to present PH-762 cancer trial data Friday By Investing.com - Investing.com South Africa
Phio Pharmaceuticals to present PH-762 cancer trial data Friday - Investing.com
Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement - marketscreener.com
A skin cancer study with 65% response sends Phio to a late-breaker stage - Stock Titan
Cancer biotech Phio Pharmaceuticals stock surges as trial shows tumor clearance at highest dose in skin cancer patients - MSN
Aug Macro: Is Phio Pharmaceuticals Corp a stock for growth or value investors2026 Historical Comparison & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Retail Trends: Is Phio Pharmaceuticals Corp being accumulated by smart money2026 Performance Recap & Daily Entry Point Trade Alerts - baoquankhu1.vn
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office - Bitget
Phio cancer study sees ~65% response; CEO in March 18 virtual chat - Stock Titan
Sidoti Boosts Earnings Estimates for Phio Pharmaceuticals - Defense World
PHIO: RNA therapy for skin cancer shows 85% response and no toxicities, advancing to pivotal trials - TradingView
Phio Pharmaceuticals Corp. Financial Disclosures & SEC Filings - TradingView
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT - GlobeNewswire
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT - TMX Newsfile
Cancer gene-silencing trial shows 65% response in Phio study - Stock Titan
How Phio Pharmaceuticals Corp. stock compares to industry benchmarksBuy Signal & High Accuracy Trade Signal Alerts - Naître et grandir
EV Market: Is Phio Pharmaceuticals Corp being accumulated by smart moneyJuly 2025 Sector Moves & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update - marketscreener.com
Cancer drug PH-762 completes safety phase as Phio raises $23.7M - Stock Titan
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - marketscreener.com
Phio cancer drug PH-762 posts 65% response; CEO hosts live Q&A - Stock Titan
PHIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients - Sahm
Phio Pharmaceuticals Corp Azioni (PHIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Phio Pharmaceuticals Corp Azioni (PHIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 23 '25 |
Buy |
1.02 |
5,000 |
5,100 |
286,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 21 '25 |
Buy |
1.14 |
5,000 |
5,700 |
281,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 18 '25 |
Buy |
1.27 |
5,000 |
6,350 |
276,421 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 10 '25 |
Buy |
2.42 |
2,000 |
4,840 |
27,149 |
| Ferrara Robert L | Director |
Jun 10 '25 |
Buy |
2.42 |
2,500 |
6,050 |
15,666 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 09 '25 |
Buy |
2.75 |
1,500 |
4,125 |
25,149 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 21 '25 |
Buy |
1.77 |
3,000 |
5,310 |
22,449 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 22 '25 |
Buy |
1.78 |
1,200 |
2,136 |
23,649 |
| Ferrara Robert L | Director |
May 20 '25 |
Buy |
1.82 |
2,500 |
4,550 |
13,166 |
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):